预约演示
Allorion scores second deal of the week in $1B pact with Avenzo
临床1期引进/卖出
Avenzo Therapeutics gained its first clinical compound Thursday, in-licensing a cancer candidate from China-based Allorion Therapeutics.
Avenzo gained ex-China global rights to AVZO-021 (formerly ARTS-021), a selective CDK2 inhibitorCDK2 inhibitor, plus an exclusive option for an undisclosed preclinical programme.
Allorion will receive $40 million upfront and is eligible for development, regulatory and commercial milestones for both programs, which could total more than $1 billion, as well as tiered royalties.
AVZO-021 is in a Phase I trial to treat HR+/HER2 metastatic breast cancer and other advanced solid tumours.
According to AllorionAllorion, CDK2 is a prime target in HR+/HER2 breast cancer because it serves as a resistance mechanism to CDK4/6-targeting therapies. Plus, the enzyme has an oncogenic role in many cyclin E1 (CCNE1) amplified cancers.
The agreement marks Allorion’s second out-licensing deal this week. On Tuesday, AstraZeneca gained an exclusive option to globally license Allorion’s EGFR L858R mutated allosteric inhibitor to treat advanced EGFR-mutant non-small-cell lung cancer in a deal valued at over $500 million.
And the deal comes just months after BeiGene grabbed its own CDK2 inhibitorCDK2 inhibitor. In November, BeiGene agreed to pay up to $1.3 billion for Ensem Therapeutics’ oral compound, ETX-197.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。